Literature DB >> 31414152

[Histiocytosis in the dermatological context of the new classification].

C Lang1, J-T Maul2, L Krähenbühl2, F Dimitriou2, R Dummer2.   

Abstract

Histiocytoses comprises a heterogeneous group of inflammatory diseases for which dendritic cells and macrophages are the main cellular components. The inflammatory infiltrate can affect the skin and other organs, and clinical outcome varies from mild to lethal depending on the involved cell subset and organ infiltration as well as comorbidities. Until recently, the group of histiocytosis was divided into Langerhans cell histiocytosis, non-Langerhans cell histiocytosis and malignant histiocytosis. With the new classification from JF Emile et al., the subgroups were determined regarding clinical, histiopathological, radiological, phenotype, genetic, and molecular features. In this review, we explain the revised classification with emphasis on dermatological and molecular aspects.

Entities:  

Keywords:  Erdheim Chester disease; Histiocytosis; Langerhans cell histiocytosis; Therapy outcome; Xanthogranuloma

Mesh:

Year:  2019        PMID: 31414152     DOI: 10.1007/s00105-019-4460-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  25 in total

1.  Xanthogranuloma is the archetype of non-Langerhans cell histiocytoses.

Authors:  B W Zelger; R Cerio
Journal:  Br J Dermatol       Date:  2001-08       Impact factor: 9.302

Review 2.  The cutaneous "histiocytoses".

Authors:  B Zelger; W H Burgdorf
Journal:  Adv Dermatol       Date:  2001

3.  Generalized eruptive histiocytomas and juvenile eruptive xanthogranulomas in a 10-year-old boy: a potpourri of exotic terms indicating the need for unification.

Authors:  Shyam B Verma
Journal:  Int J Dermatol       Date:  2012-01-10       Impact factor: 2.736

Review 4.  Raf kinases in cancer-roles and therapeutic opportunities.

Authors:  G Maurer; B Tarkowski; M Baccarini
Journal:  Oncogene       Date:  2011-05-16       Impact factor: 9.867

Review 5.  Familial and acquired hemophagocytic lymphohistiocytosis.

Authors:  G E Janka
Journal:  Annu Rev Med       Date:  2012       Impact factor: 13.739

6.  Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations.

Authors:  Louis P Dehner
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

7.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

8.  Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases.

Authors:  S A Pileri; T M Grogan; N L Harris; P Banks; E Campo; J K C Chan; R D Favera; G Delsol; C De Wolf-Peeters; B Falini; R D Gascoyne; P Gaulard; K C Gatter; P G Isaacson; E S Jaffe; P Kluin; D M Knowles; D Y Mason; S Mori; H-K Müller-Hermelink; M A Piris; E Ralfkiaer; H Stein; I-J Su; R A Warnke; L M Weiss
Journal:  Histopathology       Date:  2002-07       Impact factor: 5.087

9.  Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004.

Authors:  Aurélie Guyot-Goubin; Jean Donadieu; Mohamed Barkaoui; Stéphanie Bellec; Caroline Thomas; Jacqueline Clavel
Journal:  Pediatr Blood Cancer       Date:  2008-07       Impact factor: 3.167

10.  Incidence of Langerhans cell histiocytosis in children: a population-based study.

Authors:  Helen Stålemark; Evaldas Laurencikas; Jenny Karis; Désirée Gavhed; Bengt Fadeel; Jan-Inge Henter
Journal:  Pediatr Blood Cancer       Date:  2008-07       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.